Fig. 3: Stabilization of IFNAR1 abrogates MDSCs immune suppressive activity.

a EL-4 tumor growth in C57BL/6 WT and SA mice (n = 4). p Value is calculated in a two-way Anova test. b LLC tumor growth in mice reconstituted with WT or SA BM cells (n = 4). p Value is calculated in a two-way Anova test. c Percentage and an absolute number of M-MDSCs and PMN-MDSCs in the spleen of EL4 tumor-bearing mice (n = 2 for WT mice, n = 3 for SA mice). d Suppressive activity by PMN-MDSCs isolated from WT or SA spleen and tumors of EL4 tumor-bearing mice. Splenocytes from OT-1 mice stimulated with cognate peptide were used as effector cells. 100%—T cell proliferation without PMN-MDSCs; (spleen: n = 3 for WT mice, n = 4 for SA mice, tumor: n = 3 for all mice). p Values were calculated in unpaired Student’s t test (two-sided for spleen and one-sided for tumor). e Suppressive activity by M-MDSCs isolated from the spleen of EL4 tumor-bearing mice. 100%—T cell proliferation without M-MDSCs; (n = 3). p Values were calculated in unpaired two-sided Student’s t test. f EL4 tumor growth in WT and SA mice depleted of CD8⁺T cells. A representative of three independent experiments. p Value is calculated in a two-way Anova test. n = 3 per group. g Percentage of PMN-MDSCs in spleen from WT and SA of EL4 tumor-bearing mice depleted of CD8⁺T cells (n = 3). p Values were calculated in a one-way Anova test with correction for multiple comparisons. h Suppressive activity of HPC-derived PMN-MDSCs generated in vitro. T cell proliferation was evaluated in triplicate using [³H]-thymidine uptake (in counts per minute; CPM). Data are from one experiment representative of three experiments. p Values were calculated using unpaired two-sided Student’s t test. In all panels, data are expressed as mean ± SEM are shown. ns not significant (p > 0.05).